Last updated: 11/03/2018 19:26:08

Prevalence of patients infected with CCR5-tropic HIV-1 in Korea

GSK study ID
116696
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Prevalence of patients infected with CCR5-tropic HIV-1 in Korea
Trial description: Cross sectional study
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

prevalence of CCR5 in HIV patients

Timeframe: NA

Secondary outcomes:

Predicting factors for CCR5-tropic HIV

Timeframe: NA

Duration of viral suppression

Timeframe: NA

Interventions:
Other: NA
Enrollment:
308
Observational study model:
Other
Primary completion date:
Not applicable
Time perspective:
Cross-sectional
Clinical publications:
Not applicable
Medical condition
Infection, Human Immunodeficiency Virus
Product
maraviroc
Collaborators
Not applicable
Study date(s)
April 2013 to January 2015
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
20+ years
Accepts healthy volunteers
none
  • Subjects infected with HIV
  • older than 20 years old
  • Subjects who do not need antiviral treatment
Inclusion and exclusion criteria
Inclusion criteria:
  • Subjects infected with HIV
  • older than 20 years old
  • who need antiviral treatment
  • who signed informed consent
Exclusion criteria:
  • Subjects who do not need antiviral treatment

Trial location(s)

No location data available.

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2015-12-01

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website